- Conditions
- Heart Failure
- Interventions
- Health Guide using AHA heart failure protocols and content
- Device
- Lead sponsor
- American Heart Association
- Other
- Eligibility
- Not listed
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Warrensville Heights, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 1,447
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumors
- Interventions
- Tomivosertib (eFT-508)
- Drug
- Lead sponsor
- Effector Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more
- Conditions
- Drug Abuse
- Interventions
- Computer-delivered Brief Intervention (CBI), Intervener-delivered Brief Intervention (IBI), Adapted Motivational Enhancement Therapy (AMET), Enhanced Usual Care (EUC)
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 878 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Flint, Michigan
- Conditions
- Alcohol Drinking, Drug Abuse, HIV
- Interventions
- Motivational Network Interview
- Behavioral
- Lead sponsor
- RAND
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Santa Monica, California
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Adult enteral formula
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 54 participants
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Charleston, North Carolina
- Conditions
- Gait Disorder
- Interventions
- Balance rehabilitation + dual-tasking, Standard balance rehabilitation, Cognitive training (speed of processing), Cognitive training (general cognition)
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years to 89 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Decatur, Georgia • Mountain Home, Tennessee
- Conditions
- Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma
- Interventions
- Vactosertib(TEW-7197)/ Durvalumab
- Drug
- Lead sponsor
- MedPacto, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- San Francisco, California • Buffalo, New York
- Conditions
- Infant Development, Infant,Premature, Infant, Very Low Birth Weight, Infant, Small for Gestational Age, Infant Conditions
- Interventions
- Movement Intervention
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 3 Months to 9 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hodgkin Lymphoma
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Non Insulin Dependent Diabetes Mellitus
- Interventions
- Telehealth Bridge Visits, Standard of Care
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
- Biological · Other · Drug
- Lead sponsor
- Beat AML, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Influenza, Human
- Interventions
- Flu shot text messages
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 734,383 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Depression, Children
- Interventions
- Team-Enhanced Condition, Standard Condition
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Rectal Cancer, Non Metastatic Rectal Cancer
- Interventions
- ctDNA
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Newton, Massachusetts
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Interventions
- carfilzomib, Cytokine Assessment, Pharmacodynamic Studies, Proteosome Inhibition Assessment, Pharmacogenomic Studies
- Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Computed Tomography Perfusion Imaging
- Diagnostic Test
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Raltegravir, Dolutegravir, Colonoscopy with biopsy
- Drug · Procedure
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Suicide, Attempted
- Interventions
- Ketamine Hydrochloride, Saline, CAMS Therapy
- Drug · Behavioral
- Lead sponsor
- Tatiana Falcone, MD
- Other
- Eligibility
- 14 Years to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Smoking Cessation, Smoking, Nicotine Dependence
- Interventions
- CIS - telephone cessation quitline counseling, Lozenge - nicotine mini-lozenges, Emails - Brief smoking prevention messages, Full website - standard smokefree.gov website content, Lite website - lite version of smokefree.gov, Full mailed booklet - NCI's detailed 36-page quit guide, brief mailed booklet - smaller version of NCI's booklet
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,034 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Aggression, Anger, Posttraumatic Stress Disorder
- Interventions
- Cognitive Behavioral Therapy, Present Centered Therapy
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cerebellar Ataxia
- Interventions
- Aerobic Training, Balance Training
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Severe Sepsis, Septic Shock
- Interventions
- Pioglitazone hydrochloride
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- SARS-CoV 2 Infection, Covid19
- Interventions
- SARS-CoV2 Autoantibody detection
- Diagnostic Test
- Lead sponsor
- Namida Lab
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Neuroblastoma
- Interventions
- Naxitamab
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2036
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 18 more